CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1152-1159

  Soiffer, R J ^a   Weller, E ^a   Alyea, E P ^a   Mauch, P ^a   Webb, I L ^a   Fisher, D C ^a   Freedman, A S ^a   Schlossman, R L ^a   Gribben, J ^a   Lee, S ^a   Anderson, K C ^a   Marcus, K ^a   Stone, R M ^a   Antin, J H ^a   Ritz, J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; DONOR; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LEUKOCYTE COUNT; MALE; MORTALITY; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; WHOLE BODY RADIATION;

EID: 0035865161     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1152     Document Type: Article

References (43)

1. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
2. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
3. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donor: Single center experience
4. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated TBI
5. Marrow recipients from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
6. Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age
7. Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: Results of a phase 1 clinical trial
8. T cell depletion with CAM-PATH-1 in allogeneic bone marrow transplantation
9. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation: The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease
10. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: Comparison with cyclosporin/methotrexate
11. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease
12. Prevention of graft-versus-host-disease by selective depletion of CD6 positive T lymphocytes from donor bone marrow
13. T-cell depletion of HLA-identical transplants in leukemia
14. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion
15. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease: A prospective, randomized, double-blind trial
16. Epstein-Barr virus lymphoproliferation after bone marrow transplantation
17. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency
18. Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement: A quantitative and functional analysis
19. CD6-depleted: Allogeneic bone marrow transplantation for acute leukemia in first complete remission
20. CD6+ T cell depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma
21. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients
22. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: Identification of host-derived anti-donor allocytotoxic T lymphocytes
23. Nondeletional mechanisms of tolerance in total-lymphoid irradiation-induced bone marrow chimeras
24. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell depleted allogeneic marrow
25. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA non-identical related donors
26. Clinical manifestations of graft-versus-host disease in human recipients of HLA matched sibling donors
27. Nonparametric estimation from incomplete observations
28. A network algorithm for the exact treatment of Fisher's exact test in RxC contingency tables
29. Regression models and life tables
30. Granulocyte colony stimulating factor (G-CSF) in T cell depleted bone marrow transplantation
31. The significance of HLA-DRBi matching on clinical outcome after HLA-A, B. DR identical unrelated donor marrow transplantation
32. Total lymphoid irradiation in clinical renal transplantation-results 73 patients
33. Eight-year actuarial graft and patient survival of kidney transplants in highly immunized recipients pretreated with total lymphoid irradiation: A single-center experience
34. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia
35. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia
36. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow
37. Selective CD4+ T-cell: Depletion does not prevent graft-versus-host disease
38. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: A randomized controlled trial
39. Unrelated donor bone marrow transplantation in 5075 patients with malignant and nonmalignant disorders: Impact of marrow T cell depletion
40. Tacrolimus and minidose methotrexate for prevention of acute graft versus-host disease after matched unrelated donor marrow transplantation
41. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after bone marrow transplantation from matched unrelated donors
42. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis